Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 3Sturge-Weber Syndrome 2Neoplasms 2Nausea 2Marijuana Abuse 2Colonic Neoplasms 2Anxiety Disorders 2Vomiting 1Solid Tumor 1Parasomnias 1Pain 1Glioblastoma 1Dysgeusia 1Drug Resistant Epilepsy 1Colorectal Neoplasms 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Cachexia 1Breast Carcinoma In Situ 1Breast Cancer Female 1Arthralgia 1Appetitive Behavior 1

Interventions

Exercise 6Transcranial Direct Current Stimulation 4Neuropsychological Tests 4Walking 3Memantine 3Tablets 2Standard of Care 2Patient Reported Outcome Measures 2Methods 2Electroencephalography 2Donepezil 2Cognitive Behavioral Therapy 2mazdutide 1lime 1enzalutamide 1blueberry extract 1beta Carotene 1acetaminophen, aspirin, caffeine drug combination 1Vitamin E 1Vitamin D 1Ultraviolet Therapy 1Transcranial Magnetic Stimulation 1Time 1Therapeutics 1Tai Ji 1Surveys and Questionnaires 1Sugars 1Sodium Chloride 1Sirolimus 1Silymarin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Cognitive Dysfunction × Cannabidiol × Clear all
NCT04447846 2023-05-25

Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 2 Completed
11 enrolled 25 charts

Sturge-Weber Syndrome, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡